Senior Clinical Trial Manager

Acrivon (NASDAQ: ACRV) is a clinical stage biopharmaceutical company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 platform. The platform allows the company to interpret and quantify compound specific, drug-regulated pathway activity levels inside the intact cell in an unbiased manner, yielding terabytes of proprietary data and delivering rapid, actionable insights. The Generative Phosphoproteomics AP3 platform is comprised of a growing suite of powerful, internally-developed tools, including the AP3 Data Portal, converting multimodal data into structured data for generative AI analyses, the AP3 Kinase Substrate Relationship Predictor and the AP3 Interactome.

These distinctive capabilities enable the company to go beyond the limitations of traditional drug discovery, as well as current AI-based target-centric drug discovery, and rapidly design highly differentiated compounds with desirable pathway effects through intracellular protein network analyses and advance these agents into the clinic for streamlined development.

Acrivon is currently advancing its lead program, ACR-368 (also known as prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2b trial for endometrial cancer. The company has received Fast Track designation from the Food and Drug Administration, or FDA, for the investigation of ACR-368 as a monotherapy based on Onco Signature-predicted sensitivity in patients with endometrial cancer.

The FDA has granted a Breakthrough Device designation for the ACR-368 Onco Signature assay for the identification of patients with endometrial cancer who may benefit from ACR-368 treatment.

In addition to ACR-368, Acrivon is also leveraging its proprietary Generative Phosphoproteomics AP3 platform for developing its co-crystallography-driven, internally discovered pipeline programs. These include ACR-2316, the company’s second clinical stage asset, a novel, potent, selective WEE1/PKMYT1 inhibitor designed for superior single-agent activity through strong activation of not only CDK1 and CDK2, but also of PLK1 to drive pro-apoptotic cell death, as observed in preclinical studies against benchmark inhibitors.

The Phase 1 trial of ACR-2316 is advancing with enrollment in the first three dose-escalation cohorts completed. Drug target engagement was observed at DL1 and 2 using the company’s clinical mass-spectrometry-based AP3 profiling, with evidence of approximate dose proportionality based on plasma pharmacokinetic analyses, and initial clinical activity with tumor shrinkage observed  addition, the company is advancing a preclinical program directed against an undisclosed cell cycle regulatory target.

Our global team operates out of two leading life science clusters, Watertown, MA and Medicon Village in Lund, Sweden.

The Clinical Trial Manager (CTM) will be a key member of Acrivon Therapeutics’ Clinical Operations Team and will be responsible for providing oversight to a Phase I/II clinical trial ensuring milestones are being met. This position will be based in Watertown, MA.

• Oversees site initiation, subject enrollment, clinical monitoring, compliance at clinical sites, and metrics management with CROs, central labs, and external vendors.
• Ensures high-quality execution throughout clinical trial initiation, conduct, and closure.
• Manages study budgets, contracts with vendors, and negotiates agreements to track and control costs effectively.
• Guides cross-functional teams in achieving study timelines, strategies, goals, and quality benchmarks.
• Evaluates and ensures effective oversight of Contract Research Organizations (CROs) and other vendors, fostering strong partnerships.
• Communicates effectively with clinical trial sites to maintain project momentum.
• Updates stakeholders on trial progress to align expectations, priorities, and deliverables.
• Contributes to study-level budget development and takes responsibility for budget management.
• Identifies and addresses risks associated with clinical studies and investigator sites, implementing corrective…